Used in targeted cancer therapies, particularly in tumors exhibiting overexpression of PDGFRβ (platelet-derived growth factor receptor beta). It inhibits receptor activation, blocking downstream signaling pathways involved in cell proliferation, survival, and angiogenesis. Commonly applied in research and development for solid tumors and hematologic malignancies. Also explored in combination with chemotherapy or other targeted agents to enhance therapeutic efficacy. Its high specificity makes it valuable in diagnostic imaging and as a basis for antibody-drug conjugates.